BROADWOOD CAPITAL INC - Q4 2018 holdings

$713 Million is the total value of BROADWOOD CAPITAL INC's 8 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 33.3% .

 Value Shares↓ Weighting
STAA SellSTAAR SURGICAL CO$342,734,000
-34.2%
10,740,630
-1.1%
48.10%
-0.6%
MNST SellMONSTER BEVERAGE CORP NEW$230,316,000
-17.2%
4,679,308
-2.0%
32.32%
+25.1%
IWM  ISHARES TRrussell 2000 etf$56,238,000
-20.6%
420,0000.0%7.89%
+20.0%
AXON  AXON ENTERPRISE INC$33,253,000
-36.1%
760,0620.0%4.67%
-3.4%
BTX  BIOTIME INC$27,364,000
-61.1%
29,971,5610.0%3.84%
-41.3%
OCX  ONCOCYTE CORPORATION$10,440,000
-44.8%
7,564,9340.0%1.46%
-16.6%
AGE NewAGEX THERAPEUTICS INC$8,961,0002,997,156
+100.0%
1.26%
AST  ASTERIAS BIOTHERAPEUTICS INC$3,281,000
-52.3%
5,292,1560.0%0.46%
-28.0%
DAL ExitDELTA AIR LINES INC DELput$0-200,000
-100.0%
-1.07%
MNST ExitMONSTER BEVERAGE CORP NEWput$0-800,000
-100.0%
-4.33%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STAAR SURGICAL CO42Q3 202359.1%
MONSTER BEVERAGE CORP NEW34Q3 202349.7%
ISHARES TR33Q3 202314.8%
ONCOCYTE CORPORATION31Q2 20234.6%
BIOTIME INC25Q2 201917.8%
AXON ENTERPRISE INC24Q3 202313.4%
AGEX THERAPEUTICS INC20Q3 20231.5%
LINEAGE CELL THERAPEUTICS INC17Q3 20235.1%
ASTERIAS BIOTHERAPEUTICS INC16Q4 20182.9%
CYNOSURE INC15Q4 201610.4%

View BROADWOOD CAPITAL INC's complete holdings history.

Latest filings
TypeFiled
42024-04-15
13F-HR2024-02-14
42024-02-08
42024-01-10
42024-01-05
42023-11-30
13F-HR2023-11-14
42023-11-14
42023-11-09
42023-11-06

View BROADWOOD CAPITAL INC's complete filings history.

Compare quarters

Export BROADWOOD CAPITAL INC's holdings